Guess which obscure ASX healthcare share just exploded 220% on HUGE news

This ASX share has just tripled its investors' money.

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a pretty miserable day on the ASX share market this Wednesday. The All Ordinaries Index (ASX: XAO) finished at a heavy loss, closing 1.54% lower. But let's talk about one ASX healthcare share that decidedly bucked the markets with a gain that is almost single-handedly enough to make its shareholders wealthy.

The Zelira Therapeutics Ltd (ASX: ZLD) share price exploded in value today. This ASX healthcare share closed at 94 cents yesterday. But today's session saw the company skyrocket to close at $3.05 a share. That's an eye-watering gain of 224.5%.

Yes, you read that right. Someone with $10,000 worth of Zelira shares yesterday now has more than $30,000 worth today.

So what on earth is going on here that has prompted such a massive change in fortunes for this ASX healthcare share and its investors?

Why did ASX healthcare share Zelira rocket by 220% today?

Well, investors can likely thank a big announcement from the company this morning.

It revealed some very positive results from Zelira's cannabis-based ZLT-L-007 drug. The company has just completed a major clinical trial of ZLT-L-007 and its ability to successfully treat nerve pain.

The results of the trial revealed that ZLT-L-007 achieved significant reductions in pain scores and symptom severity against those delivered by the Pfizer-owned rival drug Lyrica. Zelira points out that Lyrica is a "multi-billion-dollar annual revenue drug".

ZLT-L-007 was also found to "be safe and well tolerated, meeting the primary endpoint for safety with no serious adverse events".

These results have prompted Zelira to "evaluate the further progression of ZLT-L-007 into formal FDA [US Food & Drug Administration] clinical trials".

Here's some of what Zelira's chair Osagie Imasogie said on this exciting news for the company:

As a commercially available pain medicine, Lyrica served as a reliable benchmark to gauge the pain relief efficacy offered by our novel candidate, ZLT-L-007. In addition, Lyrica has historically achieved peak year annual sales of approximately US$5 billion, clearly indicating the market potential for Zelira's pain relief medication that outperformed the level of pain relief from Lyrica. In certain instances, provided up to four times the observed pain relief when compared to Lyrica.

This compelling outcome gives us confidence to evaluate the further progression of ZLT-L-007 into formal FDA clinical trials.

So a very happy day for ASX healthcare share Zelira and its investors. It will be interesting to see where the company goes from here.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »